Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 31689837)

  • 1. JAK2 V617F-positive essential thrombocythemia with subsequent development of immune thrombocytopenia: A case report.
    Oda Y; Sato S; Kanbe E; Kamata W; Okada S; Tamai Y
    Medicine (Baltimore); 2019 Nov; 98(44):e17766. PubMed ID: 31689837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is the absence of JAK2 mutation a risk factor for bleeding in essential thrombocythemia? An analysis of 106 patients.
    Patriarca A; Pompetti F; Malizia R; Iuliani O; Di Marzio I; Spadano A; Dragani A
    Blood Transfus; 2010 Jan; 8(1):21-7. PubMed ID: 20104275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful eltrombopag treatment of severe refractory thrombocytopenia in chronic myelomonocytic leukemia: Two cases reports: A CARE-compliant article.
    Gao Y; Gong M; Zhang C; Kong X; Ma Y
    Medicine (Baltimore); 2017 Oct; 96(43):e8337. PubMed ID: 29069007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
    Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
    Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blast phase of essential thrombocythemia: A single center study.
    Passamonti F; Rumi E; Arcaini L; Elena C; Castagnola C; Zappasodi P; Bernasconi P; Pietra D; Pascutto C; Cazzola M; Lazzarino M
    Am J Hematol; 2009 Oct; 84(10):641-4. PubMed ID: 19691103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations.
    Al Assaf C; Van Obbergh F; Billiet J; Lierman E; Devos T; Graux C; Hervent AS; Emmerechts J; Tousseyn T; De Paepe P; Papadopoulos P; Michaux L; Vandenberghe P
    Haematologica; 2015 Jul; 100(7):893-7. PubMed ID: 25934766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia vera.
    Rottenstreich A; Kleinstern G; Krichevsky S; Varon D; Lavie D; Kalish Y
    Eur J Intern Med; 2017 Jun; 41():49-54. PubMed ID: 27919526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Megakaryopoiesis and platelet function in polycythemia vera and essential thrombocythemia patients with JAK2 V617F mutation.
    Hattori N; Fukuchi K; Nakashima H; Maeda T; Adachi D; Saito B; Yanagisawa K; Matsuda I; Nakamaki T; Gomi K; Tomoyasu S
    Int J Hematol; 2008 Sep; 88(2):181-188. PubMed ID: 18612778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High prevalence of heparin induced thrombocytopenia with thrombosis among patients with essential thrombocytemia carrying V617F mutation.
    Castelli R; Gallipoli P; Schiavon R; Teatini T; Deliliers GL; Bergamaschini L
    J Thromb Thrombolysis; 2018 Jan; 45(1):106-113. PubMed ID: 29022213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The production of JAK2 wild-type platelets is not downregulated in patients with JAK2 V617F mutant-positive essential thrombocythaemia.
    Lambert JR; Gale RE; Linch DC
    Br J Haematol; 2009 Apr; 145(1):128-30. PubMed ID: 19222478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Essential thrombocythemia during treatment of acute myeloid leukemia with JAK2 V617F mutation: A case report of a CARE-compliant article.
    Ding W; Li D; Zhuang C; Wei P; Mou W; Zhang L; Liang H; Liu Y
    Medicine (Baltimore); 2018 Jul; 97(27):e11331. PubMed ID: 29979407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules.
    Falanga A; Marchetti M; Vignoli A; Balducci D; Russo L; Guerini V; Barbui T
    Exp Hematol; 2007 May; 35(5):702-11. PubMed ID: 17577920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelets from Calreticulin mutated essential thrombocythemia patients are less reactive than JAK2 V617F mutated platelets.
    Hauschner H; Bokstad Horev M; Misgav M; Nagar M; Seligsohn U; Rosenberg N; Koren-Michowitz M
    Am J Hematol; 2020 Apr; 95(4):379-386. PubMed ID: 31868244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone marrow histomorphology and JAK2 mutation status in essential thrombocythemia.
    Stauffer Larsen T; Hasselbalch HC; Pallisgaard N; Møller MB
    APMIS; 2007 Nov; 115(11):1267-73. PubMed ID: 18092959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acquired JAK-2 V617F Mutational Analysis in Pakistani Patients with Essential Thrombocythemia.
    Sultan S; Irfan SM
    Asian Pac J Cancer Prev; 2015; 16(16):7327-30. PubMed ID: 26514532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From prednisone to pylori: a case of Helicobacter pylori-induced chronic immune thrombocytopenia.
    Hill LJ; Tung EE
    BMJ Case Rep; 2014 Jul; 2014():. PubMed ID: 25035453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK2(V617F) positive early stage myeloproliferative disease (essential thrombocythemia) as the cause of portal vein thrombosis in two middle-aged women: therapeutic implications in view of the literature.
    Michiels JJ; Commandeur S; Hoogenboom GJ; Wegman JJ; Scholten L; van Rijssel RH; De Raeve H
    Ann Hematol; 2007 Nov; 86(11):793-800. PubMed ID: 17687555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mean Platelet Volume and Platelet Distribution Width Indicate that Platelets Remain Small for Most of Their Lifespans in Patients with Essential Thrombocythemia.
    Lee E; Kim M; Jeon K; Lee J; Lee JS; Kim HS; Kang HJ; Lee YK
    Clin Lab; 2019 Apr; 65(4):. PubMed ID: 30969082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
    Bellucci S; Michiels JJ
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.